Monopar Therapeutics Inc

MNPR remains in a sustained uptrend above its 50- and 200-day SMAs, but is consolidating in a descending triangle beneath the $115 resistance and below the short-term EMAs. Volume contraction and neutral momentum argue for patience. Entries should be deferred until price either proves support near the 50-day SMA around $102 or shows clear breakout and acceptance above the $115–$113 zone.

• ↑Pending ALXN1840 NDA targets Wilson disease approval catalyst
• ↑Rising 13F ownership indicates strong institutional support
• ↓Negative earnings yield and cash burn raise valuation concerns